By the end of the presentation, attendees will be able to:

1. Understand the population where nirmatrelvir-ritonavir has been shown to be effective at reducing serious outcomes and identity the populations where nirmatrelvir-ritonavir is commonly prescribed.
2. Name the top 5 drug-drug interactions in older adults with polypharmacy who are prescribed nirmatrelvir-ritonavir.
3. Identify medication management strategies for common drug-drug interactions, including the risks and benefits of pursuing (or not) treatment with nirmatrelvir-ritonavir vs deprescribing potentially inappropriate and interacting medications.
4.  Recognize where there is a lack of evidence and where more research is needed.

MainPro+/MOC Section 1 credits: 1.0. Those who register and attend the webinar and complete the evaluation will receive their certificate.